Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection

被引:16
作者
Bassyouni, Iman H. [2 ]
Ezzat, Yasser [3 ]
Hamdy, Sherif [4 ]
Talaat, Roba M. [1 ]
机构
[1] Minofiya Univ, Dept Mol Biol, GEBRI, Minofiya, Egypt
[2] Cairo Univ, Dept Rheumatol & Rehabil, Fac Med, Cairo, Egypt
[3] Fayoum Univ, Dept Rheumatol & Rehabil, Fac Med, Al Fayyum, Egypt
[4] Cairo Univ, Dept Trop Med, Fac Med, Cairo, Egypt
关键词
anti-cyclic citrullinated peptide (anti-CCP); cryoglobulins; hepatitis C virus (HCV); rheumatoid arthritis (RA); rheumatoid factor (RF); RHEUMATOID-ARTHRITIS; AUTOANTIBODIES; MANIFESTATIONS; DIAGNOSIS; CCP;
D O I
10.1515/CCLM.2009.189
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Symmetric polyarthritis associated with hepatitis C virus (HCV) infection frequently displays a clinical picture like rheumatoid arthritis (RA). Antibodies to cyclic citrullinated peptide (CCP) have high specificity for the diagnosis of RA. This study examined the frequency and clinical significance of anti-CCP antibodies in patients with chronic HCV infection, with and without manifestations of joint involvement, compared to RA patients. Methods: Serum anti-CCP antibodies and rheumatoid factor (RF) were evaluated in 30 patients with RA and 47 patients with chronic HCV infection. Of those with HCV infection, 20 patients had chronic HCV infection associated with articular involvement and 27 patients had chronic HCV infection without any articular involvement. Results: Anti-CCP antibody level was positive in 70% of RA patients, 8.5% of HCV-infected patients, and in 20% of HCV patients with articular manifestations. RF was positive in 76% of RA patients and in 60% of HCV patients with articular involvement. Cryoglobulins were found in 29% of HCV-infected patients and in 16% of RA patients. Cryoglobulins were more frequent among HCV patients with articular affection (35%) compared to HCV patients without articular affection (26%). Conclusions: Although anti-CCP antibodies remain a useful diagnostic tool for RA, their interpretation in HCV-infected patients with arthritis should be applied with caution. The possibility that those patients could be prone to develop RA cannot be ruled out. Those patients need careful clinical and radiological follow-up. Further large-scale studies are warranted. Clin Chem Lab Med 2009; 47: 842-7.
引用
收藏
页码:842 / 847
页数:6
相关论文
共 32 条
[1]   Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation [J].
Alenius, GM ;
Berglin, E ;
Dahlqvist, SR .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (03) :398-400
[2]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[3]   Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis [J].
Bas, S ;
Genevay, S ;
Meyer, O ;
Gabay, C .
RHEUMATOLOGY, 2003, 42 (05) :677-680
[4]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[5]  
Bianchi Francesco B, 2007, Dig Liver Dis, V39 Suppl 1, pS22
[6]   Antibodies to citruillinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis [J].
Bizzaro, Nicola .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (02) :150-157
[7]   Complete nucleotide sequence of a type 4 hepatitis C virus variant, the predominant genotype in the Middle East [J].
Chamberlain, RW ;
Adams, N ;
Saeed, AA ;
Simmonds, P ;
Elliott, RM .
JOURNAL OF GENERAL VIROLOGY, 1997, 78 :1341-1347
[8]   Anti-cyclic citrullinated peptide antibodies in type 1 autoimmune hepatitis [J].
Fusconi, M ;
Vannini, A ;
Dall'Aglio, AC ;
Pappas, G ;
Cassani, F ;
Ballardini, G ;
Frisoni, M ;
Grassi, A ;
Bianchi, FB ;
Zauli, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (10) :951-955
[9]  
Girbal-Neuhauser E, 1999, J IMMUNOL, V162, P585
[10]  
Girelli F, 2004, Eur Ann Allergy Clin Immunol, V36, P127